CANVAS – Canagliflozin a kardiovaskulární a renální vliv u diabetes mellitus 2. Typu

VÍTOVEC, Jiří, Jindřich ŠPINAR a Lenka ŠPINAROVÁ. CANVAS – Canagliflozin a kardiovaskulární a renální vliv u diabetes mellitus 2. Typu. Kardiologická revue. Ambit Media a.s., 2019, roč. 21, č. 1, s. 15 - 18. ISSN 1212-4540.

Základní údaje

Originální název

CANVAS – Canagliflozin a kardiovaskulární a renální vliv u diabetes mellitus 2. Typu

Autoři

VÍTOVEC, Jiří, Jindřich ŠPINAR a Lenka ŠPINAROVÁ

Vydání

Kardiologická revue, Ambit Media a.s. 2019, 1212-4540

---

Další údaje

Jazyk

čeština

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Canagliflozin; Cardiovascular and renal safety; Programme CANVAS; Type 2 diabetes mellitus

---

Anotace

V originále

Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycaemia as well as blood pressure, body weight, and albuminuria in people with diabetes. The CANVAS Programme integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Conclusions: In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a significantly lower risk of cardiovascular events than those who received placebo. A boundary higher risk of amputation, primarily at the level of the toe or metatarsus was observed in the study. These complications, however, were not proved in subsequent observational databases. © 2019, Ambit Media a.s.. All rights reserved.